Seeking to reduce a rising tide of shortages, the Food and Drug Administration is considering the idea of creating a system to rate manufacturing facilities run by drug makers.
The hope is that customers — notably, group purchasing organizations for hospitals, but also consumers — would reward drug companies that consistently make medicines that conform to quality standards. In doing so, this could yield steady sales that would, in turn, provide incentives for further investment in facilities and, hopefully, lessen the likelihood of the sorts of quality issues that lead to shortages.
About the Author Reprints
